Autoantibody profile in progressive systemic sclerosis as markers for esophageal involvement

J Clin Gastroenterol. 2001 Feb;32(2):123-7. doi: 10.1097/00004836-200102000-00006.

Abstract

We investigated the relationship between the severity and extent of esophageal involvement in patients with progressive systemic sclerosis (PSS) and the autoantibody profile. We studied 37 consecutive patients with PSS and compared their results to 25 healthy volunteers. Patients with PSS were separated into three subgroups: group 1 (antinuclear antibody [ANA] [+/-], anti-Sc170 antibody [Scl70] [-], and anticentromere antibody [ACA] [-]), group 2 (ANA [+], Scl70 [+], and ACA [-]), and group 3 (ANA [+], Scl70 [-], and ACA [+]). The lower esophageal sphincter pressure and the mean proximal esophageal amplitude were significantly lower in group 3 when compared with group 1, group 2, and the healthy controls. Distal esophageal aperistalsis was noted in 85% of group 3, 40% of group 2, and 30% of group 1. An involvement of esophageal motility was found in 100% of the patients with ACA. Our results suggest that esophageal involvement is more pronounced in patients with PSS with ACA as compared with patients with only Sc170 or ANA.

MeSH terms

  • Adult
  • Antibodies, Antinuclear / blood
  • Autoantibodies / blood*
  • CREST Syndrome / diagnosis
  • CREST Syndrome / immunology
  • Centromere / immunology
  • DNA Topoisomerases, Type I
  • Esophageal Motility Disorders / diagnosis
  • Esophageal Motility Disorders / immunology*
  • Female
  • Gastroesophageal Reflux / diagnosis
  • Gastroesophageal Reflux / immunology
  • Humans
  • Male
  • Middle Aged
  • Nuclear Proteins / immunology
  • Peristalsis / immunology
  • Prognosis
  • Scleroderma, Systemic / diagnosis
  • Scleroderma, Systemic / immunology*

Substances

  • Antibodies, Antinuclear
  • Autoantibodies
  • Nuclear Proteins
  • Scl 70 antigen, human
  • DNA Topoisomerases, Type I